https://www.thebodypro.com/author/paul-dalton

Latest by Paul Dalton

Promo Image

Study Shows People Can Safely Switch to Atripla

Results from a study presented at the joint 2008 ICAAC/IDSA meeting in Washington, DC found that people on a stable, suppressive HIV regimen can maintain control of their HIV if they switch to the fixed-dose combination pill Atripla (efavirenz + teno...

Promo Image

Switch to Viramune Safe for Some Who Can't Tolerate Sustiva

A poster presented at the joint 2008 ICAAC/IDSA meeting in Washington, DC found that it was generally safe to substitute Viramune (nevirapine) for Sustiva (efavirenz) when people were experiencing unacceptable side effects. The study, while small, ma...

Promo Image

Study Data Explain Raltegravir's Excellent Resistance Profile

A presentation at the 2008 ICAAC in Washington, DC helps deepen our understanding of Merck's integrase inhibitor, Isentress (raltegravir). The talk by Daria Hazuda showed how resistance develops to Isentress and poses a possible explanation for its u...

Promo Image

The Coming Crisis

The last few years have witnessed remarkable progress in treating people with advanced and drug-resistant strains of HIV. Four powerful drugs became available that either overcame drug resistance (Prezista [darunavir, TMC-114], Intelence [etraviri...

Promo Image
News

Can You Safely Have Sex Without a Condom? A Calm, Careful Look at the Evidence

In January 2008, the Swiss AIDS Commission issued a controversial report on the transmission of HIV in heterosexual mixed status couples. The report stated that HIV is not likely to be passed on when the positive partner fully adhered to a potent HIV...

Promo Image
Tuberculosis

FDA Issues "Black Box" Warning for Cipro, Similar Drugs

The Food and Drug Administration (FDA) has added a "black box" warning for fluoroquinolones, a type of antibiotic that includes Cipro (ciprofloxacin) and Levaquin (levafloxacin). The warning refers to an increased risk of tendon problems, including t...

Promo Image

The Coming Crisis in HIV Drug Development

The last few years have seen tremendous progress in treating people with advanced and drug-resistant HIV. Four powerful drugs became available that either overcame drug resistance (Prezista [darunavir, TMC-114], Intelence [etravirine, TMC-125]) o...

Promo Image

Incyte Halts Development of Promising New CCR5 Drug

Incyte Pharmaceuticals recently announced their decision to halt development of their experimental HIV drug, INCB9471. INCB9471 is a type of HIV drug called a CCR5 antagonist, which looked promising in early clinical studies. The company claims it is...

Promo Image

Update From CROI 2008 on Approved HIV Drugs

The Conference on Retroviruses and Opportunistic Infections is the most important annual science conference in the US covering HIV/AIDS. This year's meeting was held in Boston, MA and included presentations ranging from vaccines to microbicides and e...

Promo Image

Update From CROI 2008 on Experimental Drugs

Compared to the recent fast pace of new HIV drug development, the next couple of years look relatively quiet. In just over two years, five new drugs were approved by the FDA, including ones from two new classes. While most people -- including those w...